Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis (Q22251177)

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Negative symptoms in schizophrenia. Definition and reliability

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Glycine agonists: what can they teach us about schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

A separate disease within the syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Treatment of negative and cognitive symptoms

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Generation of allocation sequences in randomised trials: chance, not choice

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Allocation concealment in randomised trials: defending against deciphering

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Network interactions in schizophrenia - therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

D-amino acids as putative neurotransmitters: focus on D-serine

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Five-factor model of schizophrenia. Initial validation

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

STATISTICAL TREATMENT OF THE LAW OF INITIAL VALUES (LIV) IN AUTONOMIC RESEARCH: A REVIEW AND RECOMMENDATION.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Understanding controlled trials. Crossover trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Systematic reviews from astronomy to zoology: myths and misconceptions

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Dopamine in schizophrenia: a review and reconceptualization

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FJ.SCHRES.2004.05.005

7 January 2021